To include your compound in the COVID-19 Resource Center, submit it here.

Inventiva and AbbVie discontinue development of RORgamma agonist

The partners also said they extended a deal to discover and develop a new

Read the full 142 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE